A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN).

@article{Limaye2013ARP,
  title={A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN).},
  author={Sewanti Atul Limaye and Sarah J. Riley and Sihai Zhao and Anne M. O'Neill and Marshall R. Posner and Douglas A. Adkins and Zachary Jaffa and John Garner Clark and Robert I. Haddad},
  journal={Oral oncology},
  year={2013},
  volume={49 8},
  pages={
          835-41
        }
}
OBJECTIVES There are limited chemotherapeutic options for advanced recurrent or metastatic SCCHN. The efficacy and toxicity of docetaxel with or without vandetanib was investigated in these patients. MATERIALS AND METHODS Patients with pathologically confirmed, recurrent or metastatic SCCHN who had progressed on platinum based therapy given as definitive or palliative treatment, were randomized in this open label, multicenter phase II study of docetaxel (75 mg/m2 IV Q3 weeks) with or without… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 18 CITATIONS

Angiogenesis in Head and Neck Cancer

VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED